Stock Research: Johnson & Johnson

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Johnson & Johnson

NYSE:JNJ US4781601046
60
  • Value
    60
  • Growth
    63
  • Safety
    Safety
    63
  • Combined
    68
  • Sentiment
    34
  • 360° View
    360° View
    60
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Johnson & Johnson researches, develops, manufactures, and sells healthcare products. It operates in the healthcare field through two segments: Innovative Medicine and MedTech. Medicines are distributed worldwide. In the last fiscal year, the company had a market cap of $373,350 million, profits of $61,385 million, revenue of $88,821 million, and 138,100 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Johnson & Johnson are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Johnson & Johnson. The consolidated Value Rank has an attractive rank of 63, which means that the share price of Johnson & Johnson is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 63% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 63, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 60. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 34. Professional investors are more confident in 66% other stocks. ...read more

more
Index
Dow Jones
Dividends USA
Diversity USA
Human Rights
Moonshot Tech
D.J. US Pharmaceutical
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 51 60 65
Growth
63 41 25 51
Safety
Safety
60 56 73 72
Sentiment
34 54 10 75
360° View
360° View
60 43 27 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
20 26 17 38
Opinions Change
54 50 6 66
Pro Holdings
n/a 94 76 36
Market Pulse
27 37 26 86
Sentiment
34 54 10 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 51 60 65
Growth
63 41 25 51
Safety Safety
60 56 73 72
Combined
68 45 56 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
53 48 54 58
Price vs. Earnings (P/E)
24 24 20 20
Price vs. Book (P/B)
15 12 18 20
Dividend Yield
94 94 96 96
Value
63 51 60 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
43 33 34 27
Profit Growth
48 35 46 66
Capital Growth
51 58 23 42
Stock Returns
63 51 49 75
Growth
63 41 25 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
55 51 55 67
Refinancing
11 12 21 13
Liquidity
94 96 98 96
Safety Safety
60 56 73 72

Similar Stocks

Discover high‑ranked alternatives to Johnson & Johnson and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.